Dr. Amir Fathi Interprets the Latest Developments in Targeted Therapy for Acute Myeloid Leukemia (AML)

Dr. Amir Fathi Interprets the Latest Developments in Targeted Therapy for Acute Myeloid Leukemia (AML)

The annual European Hematology Association (EHA) meeting was successfully held both online and offline from June 8th to 11th, 2023, local time, in Frankfurt, Germany. As the largest international conference in the European hematology field, it attracts over ten thousand professionals from more than 100 countries every year, sharing and discussing innovative ideas and the latest scientific and clinical research results in hematology. At this EHA meeting, Professor Amir Fathi from Harvard Medical School (HMS) presented orally on a project titled "Activity, Tolerability, and Resistance of menin Inhibitor Ziftomenib in Adult Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia (AML) Patients". Oncology Frontier invited Dr. Amir Fathi to interpret this research and the related developments in AML targeted therapy.
Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell

Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell

Intravascular Large B-Cell Lymphoma (IVLBCL) is a subtype of large B-cell lymphoma, characterized by large tumor B-cells aggregating inside blood vessels. This disease is extremely rare and highly malignant, often involving the central nervous system, lungs, and skin. Its prognosis is poor and clinical treatment challenging. At the recently concluded 28th European Hematology Association (EHA) Annual Meeting, a study (Abstract Number: P1185) from Dr. Daobin Zhou's team at Peking Union Medical College Hospital was selected. This study evaluated the efficacy and safety of the Zanubrutinib combined with R-CHOP regimen in treating initial IVLBCL, attracting widespread attention. To further understand this study, the Oncolgy Fronter invited Dr. Zhou for a detailed interpretation and analysis, summarized as follows: IVLBCL is a rare type of aggressive B-cell lymphoma that does not form a tumor mass. Its diagnosis is difficult and lacks an established standard treatment. Zanubrutinib is a novel Bruton kinase inhibitor. Recent studies have shown that Zanubrutinib has good therapeutic effects in B-cell lymphomas originating from activated B-cells, those with dual expression, and those with MYD88 mutations.
Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

From June 8th to 11th, 2023, the 28th European Hematology Association Congress (EHA) will take place in Frankfurt, Germany, in both online and offline formats, organized by the European Hematology Society. As the largest international conference in the field of European hematology, the EHA Congress will cover various scientific topics, clinical and basic research, benign and malignant hematology, and discuss the latest developments in the field of hematology. At this year's EHA Congress, a study from Italy (abstract S231) explored the differences in the efficacy and survival outcomes of CAR-T cell therapy for different subtypes of B-cell lymphoma patients, drawing significant attention. To gain a deeper understanding of this study, Oncology Frontier conducted an exclusive interview with Professor Wang Huaqing from Tianjin People's Hospital of Nankai University, who provided detailed insights into the research.
Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

From June 8 to 12, 2023, the 28th European Hematology Association (EHA) Congress will be held in Frankfurt, Germany, bringing together experts and scholars from around the world to present exciting advances in research. In the field of hematology testing, multi-parameter flow cytometry (MFC) is an important clinical diagnostic method, and the development of fast, simple, and efficient protocols is essential for this technology. A real-world study (P588) conducted by Dr.  Hui Wang's team from Hebei Yanda Ludaopei Hospital and Beijing Ludaopei Hospital has been selected for presentation at EHA. The study aims to introduce the research achievements of Ludaopei Hospital over the years: a rapid, simple, and efficient MFC test for screening and diagnosing malignant tumors and related diseases. To gain a deeper understanding of this research, "Oncology Insight" invited Professor Wang Hui to provide a detailed analysis, which is summarized below.
Dr.  Huilai Zhang’s Team: Key Research in the Field of Hodgkin Lymphoma

Dr.  Huilai Zhang’s Team: Key Research in the Field of Hodgkin Lymphoma

The 28th European Hematology Conference/Annual Meeting (28th EHA Congress) was successfully held in Frankfurt, Germany from June 8-11, 2023. The conference was organized by the European Hematology Association (EHA). As one of the largest international conferences in the field of hematology worldwide, the EHA annual meeting gathered top hematology experts from around the globe, covering all aspects of hematology research. The conference featured oral presentations, poster presentations, and several other sessions. This edition of Oncology Frontier focuses on key clinical studies on Hodgkin lymphoma presented in the oral report session, providing a quick overview of the latest research advancements in this area.
Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) was held in Frankfurt, Germany, both online and offline. The conference was hosted by the European Hematology Association. As the largest international conference in the European hematology field, it attracts over 10,000 professionals from more than 100 countries each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At the EHA conference site, Oncology Frontier specially invited Professor Niels Van de Donk from Amsterdam University Medical Center (AMC-UvA) to interpret the latest research and future direction of CAR-T in the treatment of relapsed/refractory multiple myeloma (RRMM)
Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian's team from Peking University People's Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the conference, the "Tumor Watch" publication interviewed Dr. Qian Jiang, who elaborated on the current status of CML treatment, future prospects, and the initial intent and primary outcomes of the dosage reduction study.